Literature DB >> 15130048

Tests for comparing mark-specific hazards and cumulative incidence functions.

Peter B Gilbert1, Ian W McKeague, Yanqing Sun.   

Abstract

It is of interest in some applications to determine whether there is a relationship between a hazard rate function (or a cumulative incidence function) and a mark variable which is only observed at uncensored failure times. We develop nonparametric tests for this problem when the mark variable is continuous. Tests are developed for the null hypothesis that the mark-specific hazard rate is independent of the mark versus ordered and two-sided alternatives expressed in terms of mark-specific hazard functions and mark-specific cumulative incidence functions. The test statistics are based on functionals of a bivariate test process equal to a weighted average of differences between a Nelson-Aalen-type estimator of the mark-specific cumulative hazard function and a nonparametric estimator of this function under the null hypothesis. The weight function in the test process can be chosen so that the test statistics are asymptotically distribution-free. Asymptotically correct critical values are obtained through a simple simulation procedure. The testing procedures are shown to perform well in numerical studies, and are illustrated with an AIDS clinical trial example. Specifically, the tests are used to assess if the instantaneous or absolute risk of treatment failure depends on the amount of accumulation of drug resistance mutations in a subject's HIV virus. This assessment helps guide development of anti-HIV therapies that surmount the problem of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15130048     DOI: 10.1023/b:lida.0000019253.69537.91

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  12 in total

1.  Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol.

Authors:  H F Günthard; A J Leigh-Brown; R T D'Aquila; V A Johnson; D R Kuritzkes; D D Richman; J K Wong; R T D'aquila
Journal:  Virology       Date:  1999-06-20       Impact factor: 3.616

2.  Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.

Authors:  A J Brown; H F Günthard; J K Wong; R T D'Aquila; V A Johnson; D R Kuritzkes; D D Richman
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

Review 3.  Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

Authors:  P Gilbert; S Self; M Rao; A Naficy; J Clemens
Journal:  J Clin Epidemiol       Date:  2001-01       Impact factor: 6.437

4.  A nonidentifiability aspect of the problem of competing risks.

Authors:  A Tsiatis
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

5.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

6.  Statistical analysis of quality of life data in cancer clinical trials.

Authors:  M Olschewski; M Schumacher
Journal:  Stat Med       Date:  1990-07       Impact factor: 2.373

7.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; A J Brown; A V Savara; J D Hazelwood; R T D'Aquila
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens.

Authors:  P B Gilbert; G J Hanna; V De Gruttola; J Martinez-Picado; D R Kuritzkes; V A Johnson; D D Richman; R T D'Aquila
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

Review 9.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

10.  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Authors:  R T D'Aquila; M D Hughes; V A Johnson; M A Fischl; J P Sommadossi; S H Liou; J Timpone; M Myers; N Basgoz; M Niu; M S Hirsch
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391

View more
  10 in total

1.  Mark-specific hazard ratio model with missing multivariate marks.

Authors:  Michal Juraska; Peter B Gilbert
Journal:  Lifetime Data Anal       Date:  2015-10-28       Impact factor: 1.588

2.  Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Comput Stat Data Anal       Date:  2014-12-03       Impact factor: 1.681

3.  Mark-specific additive hazards regression with continuous marks.

Authors:  Dongxiao Han; Liuquan Sun; Yanqing Sun; Li Qi
Journal:  Lifetime Data Anal       Date:  2016-05-11       Impact factor: 1.588

4.  Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Biostatistics       Date:  2012-07-03       Impact factor: 5.899

5.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.

Authors:  Yanqing Sun; Peter B Gilbert; Ian W McKeague
Journal:  Ann Stat       Date:  2009-02-01       Impact factor: 4.028

6.  A Hybrid Approach for the Stratified Mark-Specific Proportional Hazards Model with Missing Covariates and Missing Marks, with Application to Vaccine Efficacy Trials.

Authors:  Yanqing Sun; Li Qi; Fei Heng; Peter B Gilbert
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2020-05-22       Impact factor: 1.864

7.  Nonparametric Two-Sample Tests of the Marginal Mark Distribution with Censored Marks.

Authors:  Brent A Johnson
Journal:  Scand Stat Theory Appl       Date:  2017-02-16       Impact factor: 1.396

8.  On Huberized calibration regression for censored medical cost data.

Authors:  Brent A Johnson
Journal:  Stat Biosci       Date:  2015-03-04

9.  Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.

Authors:  Yanqing Sun; Peter B Gilbert
Journal:  Scand Stat Theory Appl       Date:  2012-03       Impact factor: 1.396

10.  Variable selection for a mark-specific additive hazards model using the adaptive LASSO.

Authors:  Dongxiao Han; Lianqiang Qu; Liuquan Sun; Yanqing Sun
Journal:  Stat Methods Med Res       Date:  2021-07-15       Impact factor: 2.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.